1. Home
  2. EVO vs JBGS Comparison

EVO vs JBGS Comparison

Compare EVO & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • JBGS
  • Stock Information
  • Founded
  • EVO 1993
  • JBGS 2016
  • Country
  • EVO Germany
  • JBGS United States
  • Employees
  • EVO N/A
  • JBGS N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • JBGS Real Estate Investment Trusts
  • Sector
  • EVO Health Care
  • JBGS Real Estate
  • Exchange
  • EVO Nasdaq
  • JBGS Nasdaq
  • Market Cap
  • EVO 1.2B
  • JBGS 1.4B
  • IPO Year
  • EVO 2021
  • JBGS 2017
  • Fundamental
  • Price
  • EVO $3.48
  • JBGS $22.79
  • Analyst Decision
  • EVO Buy
  • JBGS Sell
  • Analyst Count
  • EVO 2
  • JBGS 2
  • Target Price
  • EVO $5.40
  • JBGS $16.00
  • AVG Volume (30 Days)
  • EVO 52.1K
  • JBGS 1.1M
  • Earning Date
  • EVO 11-05-2025
  • JBGS 10-28-2025
  • Dividend Yield
  • EVO N/A
  • JBGS 3.08%
  • EPS Growth
  • EVO N/A
  • JBGS N/A
  • EPS
  • EVO N/A
  • JBGS N/A
  • Revenue
  • EVO $912,894,891.00
  • JBGS $513,301,000.00
  • Revenue This Year
  • EVO $0.43
  • JBGS N/A
  • Revenue Next Year
  • EVO $9.72
  • JBGS $2.33
  • P/E Ratio
  • EVO N/A
  • JBGS N/A
  • Revenue Growth
  • EVO N/A
  • JBGS N/A
  • 52 Week Low
  • EVO $2.84
  • JBGS $13.28
  • 52 Week High
  • EVO $5.64
  • JBGS $22.76
  • Technical
  • Relative Strength Index (RSI)
  • EVO 39.62
  • JBGS 75.21
  • Support Level
  • EVO $3.36
  • JBGS $21.03
  • Resistance Level
  • EVO $3.52
  • JBGS $21.45
  • Average True Range (ATR)
  • EVO 0.08
  • JBGS 0.57
  • MACD
  • EVO 0.00
  • JBGS 0.15
  • Stochastic Oscillator
  • EVO 31.58
  • JBGS 98.83

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.

Share on Social Networks: